Click to View in Browser
Wednesday, September 20, 2017
Novartis's Rydapt wins EU approval for AML, other diseases
ZURICH (Reuters) - Swiss drugmaker Novartis on Wednesday said it had won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases, adding to U.S. approvals it secured in April.
GSK's new triple lung drug beats other modern inhalers in study
LONDON (Reuters) - GlaxoSmithKline produced clinical data on Wednesday showing its newly approved three-in-one inhaler reduced life-threatening attacks in chronic obstructive pulmonary disease (COPD) patients more than other modern treatments.
Unbudgeted: How the opioid crisis is blowing a hole in small-town America's finances
INDIANA, Pa./CHILLICOTHE, Ohio (Reuters) - As deaths mount in America's opioid crisis, communities on the front lines face a hidden toll: the financial cost.
As clock ticks, Republicans try to move ahead on Obamacare repeal
WASHINGTON (Reuters) - The Trump administration and top U.S. Senate Republicans pushed on Tuesday for action on a bill to dismantle Obamacare, but time was running out and they were still hunting for the votes needed to pass their latest attempt to gut the 2010 healthcare law.
Shire, Shionogi's ADHD drug for adults clears late-stage trial in Japan
TOKYO (Reuters) - Shire Plc and Shionogi & Co Ltd said a drug to treat ADHD in adults had met its main goal in a late-stage trial in Japan, bringing it one step closer to approval in the world's third-biggest market for ADHD treatments.
What can studies tell us about whole grains and the heart?
(Reuters Health) - Scientists haven’t yet proved beyond a doubt that a diet rich in whole grains is healthy for the heart, a research review suggests.
Hospital allow kids to drive themselves to operating room
LOS ANGELES (Reuters) - A San Diego children's hospital unveiled a collection of remote controlled luxury mini cars on Tuesday that allow its young patients to 'drive' themselves to the operating room.
UK backs Opdivo for lung cancer after Bristol-Myers cuts price
LONDON (Reuters) - Bristol-Myers Squibb's immunotherapy drug Opdivo has been recommended for some patients with lung cancer by Britain's healthcare cost watchdog NICE after the drugmaker agreed a discounted price.
Poor sleep associated with higher risk of chronic pain
(Reuters Health) - People who sleep poorly may be more likely to develop a chronic pain condition and have worse physical health, a study from the UK suggests.
Energy-efficient green buildings may emit hazardous chemicals
(Reuters Health) - Newly renovated low-income housing units in Boston earned awards for green design and building but flunked indoor air-quality tests, a new study shows.
Related Video
Grow your own furniture using fungus
Making food out of air Finnish style
A quick-fix on the day's news delivered when you want it. Register Today
A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today
» » MORE NEWSLETTERS
- 3 Times Square New York, NY 10036 USA © Copyright 2017 Thomson Reuters
Ensure delivery of Reuters Newsmails, add newsletters@email.reuters.com to your address book.
Subscribe to other Reuters newsletters.
Unsubscribe from this newsletter.
Follow us on Twitter Friend us on Facebook